SCHEMBL23744154

SCHEMBL23744154

CCCc1cnc(N2C[C@@H](C)N[C@@H](C)C2)nc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.49
NPC1 O15118 2/20 0.49
RAB9A P51151 2/20 0.49
ACACB O00763 4/20 0.44
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
PTPN11 Q06124 3/20 0.40
GPR119 Q8TDV5 4/20 0.35
ALDH1A1 P00352 1/20 0.34
BCL6 P41182 1/20 0.34
NCOR2 Q9Y618 1/20 0.34
HDAC3 O15379 1/20 0.33
HDAC4 P56524 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC7 Q8WUI4 1/20 0.33
HDAC2 Q92769 1/20 0.33
HDAC10 Q969S8 1/20 0.33
HDAC11 Q96DB2 1/20 0.33
HDAC8 Q9BY41 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23744766 0.87 PTPN11 (0.41) KDM4ENPC1RAB9AACACBPTPN11
SCHEMBL23744157 0.78 PTPN11 (0.44) ACACBPTPN11GPR119BCL6NCOR2
SCHEMBL24945764 0.76 PTPN11 (0.43) PTPN11BCL6NCOR2HDAC1
SCHEMBL15725788 0.76 PTPN11 (0.49) PTPN11BCL6NCOR2HDAC1
SCHEMBL23744086 0.76 PTPN11 (0.43) PTPN11BCL6NCOR2HDAC1
SCHEMBL23744047 0.76 PTPN11 (0.51) ACACBPTPN11GPR119BCL6NCOR2
SCHEMBL23744751 0.76 PTPN11 (0.51) ACACBPTPN11GPR119BCL6NCOR2
SCHEMBL23744770 0.76 PTPN11 (0.43) KDM4EPTPN11BCL6NCOR2
SCHEMBL16307879 0.76 KDM4E (0.48) KDM4ENPC1RAB9AACACBMEN1
SCHEMBL16015955 0.75 NPC1 (0.57) KDM4ENPC1RAB9AACACBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4100410-B1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES INC (US) 2026-04-22 EP disclosed
US-20230129359-A1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES, INC. 2023-04-27 US disclosed
US-20230129359-A1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES, INC. 2023-04-27 US disclosed
US-20230129359-A1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES, INC. 2023-04-27 US disclosed
WO-2021158698-A1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES, INC. (US) 2021-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230129359-A1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE CHRM4, CHRM2, CHRM5 KDM4E 2192/4885NPC1 1236/4885RAB9A 3190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.